VIA Pharmaceuticals (VIAP) Inactive 10-Q2002 Q3 Quarterly report

Filed: 14 Nov 02, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Acquisition, adverse, adversely, alerting, approximately, Canyon, cardiovascular, ceasing, Centocor, Certification, certify, certifying, Chief, close, closing, committee, concentrate, concluded, conserve, corrective, cost, covered, data, disease, employee, ensure, execution, executive, Exhibit, exit, extent, fact, Failure, fewer, Finanical, focused, fraud, guidance, harm, Health, identified, implement, introduced, Johnson, knowledge, light, lower, measured, measurement, merger, misleading, National, newly, November, occupancy, organization, ownership, participation, paul, percent, prospectively, reduction, Reorganization, responsible, robert, role, Rule, September, sobol, space, sublet, subsequent, subsidiary, summarize, supervision, transaction, unable, untrue, varying, Vascular, VGI

Removed: adequate, continued, defining, delay, delivered, developing, enhance, expression, level, relinquish, scope, system, transfer

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

VIAP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 99.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Robert E. Sobol, M.D., Chief Executive Officer of GenStar Therapeutics Corporation (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	(1) the Quarterly Report on Form 10-Q of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of section 13(a) or 15(d)of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

	(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant for the periods covered by the Report.

Dated: November 14, 2002

	/s/ ROBERT E. SOBOL, M.D.

	Robert E. Sobol, M.D. Chief Executive Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.